Recombinant Growth Hormone Treatment in Short Patients with Thalassemia Major: Results after 24 and 36 Months
-
L. Cavallo
,
A. Acquafredda
Abstract
Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological: age (Ht SDSca) increased significantly (p = 0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSba). Median AHt SDScA/AHt SDSba was <1.0 with respect to both the start (0.87) and the end of the first year of rhGH therapy (0.89). IGF-I levels increased significantly (p = 0.043) compared with values both at the start and at the end of the first year of rhGH therapy. In Group B neither Ht SDSca : nor Ht SDSba differed statistically from starting values, the former having a positive trend and the latter a negative one. Median AHt SDScA/AHt SDSba was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p = 0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.
© 2016 by Walter de Gruyter Berlin/Boston
Artikel in diesem Heft
- Titelei
- Table of Contents
- Doping with Growth Hormone
- Intrauterine Diabetic Environment Confers Risks for Type 2 Diabetes Mellitus and Obesity in the Offspring, in Addition to Genetic Susceptibility
- Variable Presentation of X-linked Adrenal Hypoplasia Congenita
- Sustained Benefits of Growth Hormone on Body Composition, Fat Utilization, Physical Strength and Agility, and Growth in Prader-Willi Syndrome are Dose-Dependent
- Insufficient Adrenarche in Patients with Combined Pituitary Hormone Deficiency Caused by a PROP A Gene Defect
- Syndrome of Congenital Adrenocortical Unresponsiveness to ACTH. Report of Six Patients
- Maternal and Fetal Serum Insulin-like Growth Factor-I (IGF-I), IGF Binding Protein-3 (IGFBP-3), Leptin Levels and Early Postnatal Growth in Infants Born Asymmetrically Small for Gestational Age
- Relationships Between Levels of Leptin and Hematological Parameters in Healthy Term Infants
- Recombinant Growth Hormone Treatment in Short Patients with Thalassemia Major: Results after 24 and 36 Months
- Assessment of the Current Status of Iodine Prophylaxis in Bosnia and Herzegovina Federation
- Profiles of Obese Children Presenting for Metabolic Evaluation
- Effect of Growth Hormone Treatment on Hypoglycemia in a Patient with both Hepatic Glycogen Synthase and Isolated Growth Hormone Deficiencies
- Gliclazide-Induced Hepatitis, Hemiplegia and Dysphasia in a Suicide Attempt
- Neonatal Goiter Caused by Expectorant Usage
- Idiopathic Hypothalamic Dysfunction with Precocious Puberty and Adipsic Hypernatremia First Presenting in Adolescence
- Neonatal Hyperthyroidism m Infants of Mothers Previously Thyroidectomized due to Graves’ Disease
- Primary Hyperparathyroidism in an Infant with Three Parathyroid Glands and Pulmonary Calcinosis
- Asymmetric Crying Facies and Congenital Hypothyroidism: Report of Two Patients
- Obituary. Professor Dr. Andrea Prader (1919–2001)
- Meetings Calendar
- Author Index
Artikel in diesem Heft
- Titelei
- Table of Contents
- Doping with Growth Hormone
- Intrauterine Diabetic Environment Confers Risks for Type 2 Diabetes Mellitus and Obesity in the Offspring, in Addition to Genetic Susceptibility
- Variable Presentation of X-linked Adrenal Hypoplasia Congenita
- Sustained Benefits of Growth Hormone on Body Composition, Fat Utilization, Physical Strength and Agility, and Growth in Prader-Willi Syndrome are Dose-Dependent
- Insufficient Adrenarche in Patients with Combined Pituitary Hormone Deficiency Caused by a PROP A Gene Defect
- Syndrome of Congenital Adrenocortical Unresponsiveness to ACTH. Report of Six Patients
- Maternal and Fetal Serum Insulin-like Growth Factor-I (IGF-I), IGF Binding Protein-3 (IGFBP-3), Leptin Levels and Early Postnatal Growth in Infants Born Asymmetrically Small for Gestational Age
- Relationships Between Levels of Leptin and Hematological Parameters in Healthy Term Infants
- Recombinant Growth Hormone Treatment in Short Patients with Thalassemia Major: Results after 24 and 36 Months
- Assessment of the Current Status of Iodine Prophylaxis in Bosnia and Herzegovina Federation
- Profiles of Obese Children Presenting for Metabolic Evaluation
- Effect of Growth Hormone Treatment on Hypoglycemia in a Patient with both Hepatic Glycogen Synthase and Isolated Growth Hormone Deficiencies
- Gliclazide-Induced Hepatitis, Hemiplegia and Dysphasia in a Suicide Attempt
- Neonatal Goiter Caused by Expectorant Usage
- Idiopathic Hypothalamic Dysfunction with Precocious Puberty and Adipsic Hypernatremia First Presenting in Adolescence
- Neonatal Hyperthyroidism m Infants of Mothers Previously Thyroidectomized due to Graves’ Disease
- Primary Hyperparathyroidism in an Infant with Three Parathyroid Glands and Pulmonary Calcinosis
- Asymmetric Crying Facies and Congenital Hypothyroidism: Report of Two Patients
- Obituary. Professor Dr. Andrea Prader (1919–2001)
- Meetings Calendar
- Author Index
